Latest stories on XLO
Xilio Therapeutics GAAP EPS of -$0.30 beats by $0.64, revenue of $9.98M beats by $5.06M
Business Insider74 · bullishearnings
Xilio Therapeutics, Inc. (XLO) files 8-K
SEC 8-K50 · neutralgeneral
Xilio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Pipeline and Business Updates
Business Insider63 · neutralearnings
Xilio Therapeutics to Present at the Stifel 2026 Healthcare Conference
GlobeNewswire56 · neutralproduct/pr
Xilio Therapeutics to Present at the Stifel 2026 Healthcare Conference
Business Insider53 · neutralproduct/pr
Xilio Therapeutics Inc trading resumes
The Fly50 · neutralgeneral
Xilio Therapeutics Inc trading halted, volatility trading pause
The Fly42 · neutralgeneral
Xilio Therapeutics doses first patient in XTX501 trial
The Fly61 · neutralproduct/pr
Xilio Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of XTX501 in Patients with Metastatic NSCLC
GlobeNewswire63 · neutralproduct/pr
Xilio Therapeutics initiated with an Outperform at Raymond James
The Fly63 · neutralanalyst
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
StockTitan50 · neutralgeneral
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Insider50 · neutralgeneral
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire50 · neutralgeneral
Xilio Therapeutics appoints Houvras as chief medical officer
The Fly56 · neutralgeneral
Xilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer
GlobeNewswire56 · neutralgeneral
Xilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer
Business Insider56 · neutralgeneral
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire50 · neutralgeneral
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Insider50 · neutralgeneral
Xilio Therapeutics GAAP EPS of -$0.33, revenue of $18.7M
Seeking Alpha56 · neutralearnings
Xilio Therapeutics, Inc. (XLO) files 8-K
SEC 8-K50 · neutralgeneral
Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates
GlobeNewswire56 · neutralearnings
Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates
Business Insider59 · neutralproduct/pr
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | XLO Stock News
StockTitan50 · neutralgeneral
Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer | XLO Stock News
StockTitan55 · neutralgeneral
Xilio Therapeutics Adjusts Board Structure Following Shareholder Votes
TipRanks50 · neutralgeneral